Iptacopan, an oral factor B inhibitor, is currently approved under the brand name Fabhalta for the treatment of adults with PNH. Topline results were announced from a phase 3b study evaluating the ...
The FDA approved iptacopan (Fabhalta) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare but potentially fatal disorder affecting red blood cells (RBCs), ...
The phase 3 PEGASUS trial found that patients with paroxysmal nocturnal hemoglobinuria (PNH) may still experience anemia following recommended therapies, underscoring the need for further research. In ...
Paroxysmal hemicrania is a type of severe headache that can cause sudden, throbbing pain on one side of the face or behind the eye. The headaches can occur frequently throughout the day and may last ...
BEIJING & BURLINGTON, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and ...
Machine learning models can identify undiagnosed PNH cases by analyzing EHR data, potentially transforming rare disease diagnostics. PNH symptoms overlap with other conditions, leading to frequent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results